A detection system for determining lysyl oxidase-like 2 protein (LOXL2) levels in a bodily sample, includes at least one reaction solution for generating H.sub.2O.sub.2 upon combination with LOXL2 in the bodily sample, the reaction solution including lysine that can be oxidatively deaminated by LOXL2 to generate -aminoadipic--semialdehyde (allysine) and hydrogen peroxide (H.sub.2O.sub.2).

Embodiments of the present invention are directed to a semiconductor device. A non-limiting example of the semiconductor device includes a semiconductor substrate. The semiconductor device also includes a plurality of metal nanopillars formed on the substrate. The semiconductor device also includes an amperometric sensor associated with one of the plurality of nanopillars, wherein the amperometric sensor is selective to an enzyme-active neurotransmitter. The semiconductor device also includes a resistivity sensor associated with a pair of nanopillars, wherein the resistivity sensor is selective to an analyte.

Compositions containing monoamine oxidase inhibitors prepared by removal of alcohol from agave-derived beverages are disclosed.

A biosensor includes an array of electrically conductive nanorods formed on a substrate. The nanorods each includes a nanoscale porous coating formed on a surface of the nanorods from silicon dioxide layers. An enzyme coating is bound to the porous coating.

A biosensor includes an array of electrically conductive nanorods formed on a substrate. The nanorods each includes a nanoscale porous coating formed on a surface of the nanorods from silicon dioxide layers. An enzyme coating is bound to the porous coating.

A detection system for determining lysyl oxidase-like 2 protein (LOXL2) levels in a bodily sample, includes at least one reaction solution for generating H.sub.2O.sub.2 upon combination with LOXL2 in the bodily sample, the reaction solution including lysine that can be oxidatively deaminated by LOXL2 to generate -aminoadipic--semialdehyde (allysine) and hydrogen peroxide (H.sub.2O.sub.2).

Provided herein are methods that relate to a novel therapeutic strategy for treatment of heart and/or cardiovascular diseases. The method includes administration of LOXL2 inhibitors for treating, preventing, or ameliorating at least one symptom associated with heart and/or cardiovascular diseases.

Fructosyl amino acid oxidase is provided, which has an amino acid sequence as shown in SEQID. No. 1 or fructosyl amino acid oxidase having a homology of more than 80% with this amino acid sequence, on a corresponding site of an amino acid selected from following (a) to (f), having one or more amino acid residues conducting a substitution, obtained fructosyl amino acid oxidase having a higher thermostability: (a) 59-site glutamic acid, (b) 98-site glutamic acid, (c) 225-site glycine, (d) 277-site lysine, (e) 285-site glutamic acid, and (f) 355-site aspartic acid. The method for preparing the above oxidase and the test kit containing the enzyme for determining glycated albumin are also provided.

The present invention provides a novel enzyme and methods of using the enzyme for measuring glycine concentration. Specifically, the present invention provides an enzyme in which at least one amino acid residue is mutated so as to improve a property of a glycine oxidase which is associated with the measurement of glycine (e.g., activity of glycine oxidase for glycine, thermal stability of glycine oxidase, and substrate specificity of glycine oxidase for glycine,); and a method of analyzing glycine, that includes measuring glycine contained in a test sample using the modified enzyme; and the like.

The present invention relates to inhibitors of VAP-1 and their use as medicaments in treating fibrotic conditions. Furthermore, the present invention relates to a method of diagnosing a fibrotic condition on the basis of elevated level of soluble VAP-1 or SSAO activity in a bodily fluid, and to a kit for use in said diagnostic method.